Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Down 28.9% in February

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 17,842 shares, a drop of 28.9% from the January 29th total of 25,106 shares. Based on an average daily trading volume, of 79,857 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the company’s shares are short sold. Approximately 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 79,857 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, January 9th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new stake in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned approximately 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent quarter.

Hong Kong Pharma Digital Technology Trading Up 1.5%

HKPD stock opened at $0.66 on Friday. Hong Kong Pharma Digital Technology has a 1 year low of $0.63 and a 1 year high of $2.76. The stock has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $1.04.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.